GO:0004057 arginyl-tRNA--protein transferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004057 describes the enzymatic activity that transfers L-arginine from arginyl-tRNA(Arg) to the N-terminus of a protein, forming an N-terminal arginyl bond and releasing tRNA(Arg).
• The reaction is catalyzed by arginyl-tRNA--protein transferases (ATE1 in eukaryotes), which recognize specific N-terminal residues and tRNA(Arg) through a distinct catalytic domain.
• Arginylation is a post-translational modification that creates N-degrons, influencing protein stability, localization, and interactions.
• ATE1 and its homologs are implicated in cancer progression, metabolic regulation, and stress responses, making them attractive research targets.
• Structural and biochemical studies have revealed the molecular basis of tRNA recognition and catalysis, enabling targeted experimental design.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are powerful tools to dissect the physiological roles of arginyl-tRNA--protein transferase activity.
Description
Arginyl-tRNA--protein transferase activity (GO:0004057) is a molecular function that catalyzes the transfer of L-arginine from arginyl-tRNA(Arg) to the N-terminus of acceptor proteins, generating an N-terminal arginyl residue and free tRNA(Arg). This post-translational modification, known as arginylation, is conserved from yeast to humans and is mediated by the ATE1 gene product in eukaryotes. The reaction is unique among tRNA-dependent modifications because it uses tRNA as a donor of arginine for protein modification rather than for ribosomal protein synthesis. Researchers study this activity to understand how cells regulate protein stability, respond to stress, and control diverse physiological processes. The enzymatic activity is essential for N-degron pathways, where the exposed N-terminal residue after cleavage or oxidation determines protein fate. Dysregulation of arginylation has been linked to cancer, metabolic disorders, and developmental defects, underscoring its biomedical importance. This article provides a comprehensive overview of the mechanism, key genes, disease associations, and research methods for studying GO:0004057.
arginyl-tRNA--protein transferase activity At A Glance
| GO ID | GO:0004057 |
|---|---|
| GO term | arginyl-tRNA--protein transferase activity |
| Ontology | molecular_function |
| Synonym | arginine transferase activity, arginyltransferase activity, arginyl-tRNA protein transferase activity |
| Major function | Catalyzes the transfer of L-arginine from arginyl-tRNA(Arg) to the N-terminus of acceptor proteins, forming an N-terminal arginyl bond and releasing tRNA(Arg) |
| Reaction | N-terminal L-alpha-aminoacyl-[protein] + L-arginyl-tRNA(Arg) = H+ + N-terminal L-arginyl-L-amino acid-[protein] + tRNA(Arg) |
| Enzyme class | Transferase (EC 2.3.2.-) |
| Cellular context | Cytoplasm; involved in N-degron pathways and post-translational modification |
| Key enzyme | ATE1 (arginyl-tRNA--protein transferase 1) in eukaryotes |
What Is GO:0004057?
According to the Gene Ontology, GO:0004057 (arginyl-tRNA--protein transferase activity) is defined as the catalysis of the reaction: an N-terminal L-alpha-aminoacyl-[protein] + L-arginyl-tRNA(Arg) = H+ + N-terminal L-arginyl-L-amino acid-[protein] + tRNA(Arg). In simpler terms, it is the enzyme activity that attaches an arginine amino acid to the beginning (N-terminus) of a protein, using arginyl-tRNA as the arginine donor. This activity is also known by synonyms such as arginine transferase activity, arginyltransferase activity, and arginyl-tRNA protein transferase activity.
Why Is arginyl-tRNA--protein transferase activity Important in Cell Biology?
Arginyl-tRNA--protein transferase activity is critical for cellular homeostasis because it introduces a reversible post-translational modification that can alter protein stability, localization, and function. This activity is a key component of the N-degron pathway, where the N-terminal arginine acts as a degradation signal recognized by E3 ubiquitin ligases, thereby controlling the half-life of specific proteins. Beyond degradation, arginylation influences processes such as cardiovascular development, glucose metabolism, and stress responses. The enzyme ATE1 and its homologs are conserved across species, and their dysfunction has been associated with cancer, metabolic disorders, and neurodegeneration. Understanding GO:0004057 provides insights into fundamental cell biology and offers potential therapeutic targets for diseases where arginylation is dysregulated.
• Regulates protein stability through the N-degron pathway, affecting turnover of key regulatory proteins.
• Modulates glucose uptake and energy expenditure via insulin-stimulated cleavage and arginylation of TUG.
• Promotes breast cancer progression by regulating MAPK-MYC signaling.
• Involved in pexophagy through arginylation of ACAD10, linking arginylation to autophagy.
• Essential for cardiovascular development and angiogenesis in model organisms.
• Plays a role in stress responses, including oxidative stress and heat shock.
• Conserved from yeast to humans, enabling genetic studies in model systems.
• Potential target for therapeutic intervention in cancer and metabolic diseases.
• Structural insights enable rational design of inhibitors or modulators.
• Provides a paradigm for tRNA-dependent post-translational modifications beyond translation.
Molecular Mechanism of arginyl-tRNA--protein transferase activity
Substrate Recognition and Binding
In simple terms: The enzyme first grabs the arginine-carrying tRNA and the target protein.
Arginyl-tRNA--protein transferase (ATE1) specifically recognizes L-arginyl-tRNA(Arg) and an acceptor protein with a suitable N-terminal residue, such as Asp, Glu, or Cys (after oxidation). Structural studies show that the enzyme uses a distinct domain to bind the tRNA, ensuring high fidelity for arginine delivery. The acceptor protein's N-terminal region is accommodated in a binding pocket that positions the alpha-amino group for nucleophilic attack.
Catalytic Transfer of Arginine
In simple terms: The enzyme snips the arginine off the tRNA and attaches it to the protein's front end.
The catalytic mechanism involves the transfer of the arginyl moiety from the 3'-end of tRNA(Arg) to the N-terminal alpha-amino group of the acceptor protein, forming a peptide bond and releasing free tRNA(Arg). This reaction is energy-independent and does not require ATP or GTP, distinguishing it from ribosomal protein synthesis. Conserved residues in the active site, including cysteine and histidine, facilitate the transfer, as shown by biochemical and structural analyses.
Structural Basis of tRNA Recognition
In simple terms: The enzyme has a special shape that fits the tRNA like a lock and key.
Crystal structures of ATE1 in complex with tRNA(Arg) have revealed the molecular details of tRNA recognition, including interactions with the acceptor stem and anticodon loop. The enzyme uses a unique fold that is distinct from ribosomal proteins and other tRNA-binding proteins, explaining its specificity for arginyl-tRNA. These structural insights have been validated by mutagenesis studies that identified key residues required for tRNA binding and catalysis.
Regulation and Post-Translational Control
In simple terms: The activity can be turned on or off by other cellular signals.
Arginyl-tRNA--protein transferase activity is regulated at multiple levels, including enzyme abundance, subcellular localization, and post-translational modifications. For example, oxidative stress can induce the oxidation of N-terminal Cys residues, creating a substrate for arginylation and linking the activity to redox signaling. Additionally, the availability of arginyl-tRNA and the presence of specific N-degron substrates can modulate the overall rate of arginylation.
Key Genes Involved in GO:0004057 arginyl-tRNA--protein transferase activity
The following genes and proteins are central to arginyl-tRNA--protein transferase activity, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATE1 | Eukaryotic arginyl-tRNA--protein transferase; catalyzes arginine transfer to N-termini of proteins | Key enzyme for arginylation; knockout models show developmental defects and metabolic alterations |
| ATE1 (yeast) | Saccharomyces cerevisiae homolog; essential for N-degron pathway | Model for genetic and biochemical studies of arginylation |
| TUG | Acceptor protein for arginylation; involved in glucose uptake | Insulin-stimulated cleavage and arginylation regulate energy expenditure |
| ACAD10 | Acceptor protein; acyl-CoA dehydrogenase family member 10 | Arginylation of oxidized ACAD10 modulates pexophagy |
| MAPK | Signaling kinase; downstream of arginylation in cancer | ATE1 promotes breast cancer via MAPK-MYC signaling |
| MYC | Transcription factor; regulated by arginylation-dependent MAPK signaling | Oncogenic driver in breast cancer |
| RARS | Arginyl-tRNA synthetase; provides arginyl-tRNA for transfer | Supplies substrate for arginyl-tRNA--protein transferase |
| tRNA(Arg) | Arginine-specific tRNA; donor of arginine | Direct substrate in the transfer reaction |
| UBR1 | E3 ubiquitin ligase; recognizes N-terminal arginine | Links arginylation to protein degradation |
| UBR2 | E3 ubiquitin ligase; N-recognin | Potential reader of N-terminal arginine |
| UBR4 | E3 ubiquitin ligase; N-recognin | May recognize arginylated proteins |
| UBR5 | E3 ubiquitin ligase; N-recognin | Involved in N-degron pathway |
| Leishmania ATE1 | Putative aminoacyl-tRNA-protein transferase in Leishmania major | Potential drug target in parasites |
| Cys-N-degron pathway components | Regulate oxidation and arginylation of N-terminal Cys | Modulates pexophagy and stress responses |
| Insulin signaling proteins | Upstream regulators of TUG cleavage and arginylation | Link arginylation to glucose metabolism |
| Proteasome subunits | Degrade arginylated proteins | Downstream effectors of N-degron pathway |
| Autophagy machinery | Interacts with arginylated ACAD10 | Connects arginylation to pexophagy |
How Is arginyl-tRNA--protein transferase activity Regulated?
Arginyl-tRNA--protein transferase activity is regulated by multiple mechanisms. The expression and activity of ATE1 can be modulated by cellular stress, including oxidative stress and heat shock, which alter substrate availability and enzyme function. Insulin signaling stimulates the cleavage of TUG, exposing a new N-terminus that can be arginylated, thereby linking arginylation to glucose uptake and energy expenditure. Additionally, the Cys-N-degron pathway regulates the oxidation of N-terminal cysteine residues, creating a substrate for arginylation and controlling pexophagy. At the protein level, ATE1 activity may be influenced by post-translational modifications and interactions with other proteins, although the precise mechanisms require further study.
arginyl-tRNA--protein transferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ATE1 | Breast cancer progression | Knockout or knockdown in breast cancer cell lines; xenograft mouse models |
| ATE1 | Metabolic disorders (insulin resistance) | Conditional knockout in mouse adipose or muscle tissue; glucose tolerance tests |
| ACAD10 | Pexophagy and metabolic stress | Knockout or point mutation in cell lines; autophagy flux assays |
| Leishmania ATE1 | Parasitic infection | Gene knockout in Leishmania major; macrophage infection models |
| TUG | Glucose uptake and energy expenditure | Knock-in of arginylation-deficient TUG mutant; insulin stimulation assays |
Cancer
ATE1-mediated arginylation promotes breast cancer progression by regulating MAPK-MYC signaling. Knockdown of ATE1 reduces tumor growth and metastasis in xenograft models, suggesting that arginyl-tRNA--protein transferase activity is a potential therapeutic target. The enzyme may also affect other cancers through its role in protein stability and stress responses.
Metabolic Disorders
Arginylation of TUG is stimulated by insulin and is required for glucose uptake and energy expenditure. Dysregulation of this pathway may contribute to insulin resistance and obesity, making ATE1 a candidate for metabolic disease research.
Neurodegeneration
The N-degron pathway, including arginylation, is implicated in the clearance of misfolded proteins and neuronal survival. Defects in arginylation could lead to accumulation of toxic proteins, although direct evidence in human neurodegeneration is still emerging.
Infectious Diseases
Leishmania major possesses a putative aminoacyl-tRNA-protein transferase that may be essential for parasite survival, representing a potential drug target. Further studies are needed to validate its role in infection.
From arginyl-tRNA--protein transferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the role of ATE1 in development? | Ate1 knockout mouse (embryonic lethal) or conditional knockout |
| How does arginylation affect protein stability? | Point mutation of acceptor N-terminal residue (e.g., Asp to Ala) in cell lines |
| What are the substrates of arginylation? | Knock-in of tagged ATE1 or substrate proteins; proteomics |
| Does ATE1 promote cancer? | Overexpression of ATE1 in cancer cell lines; xenograft models |
| How is arginylation regulated by insulin? | Knockout of TUG cleavage site; insulin stimulation in adipocytes |
| What is the structural basis of tRNA recognition? | Recombinant ATE1 and tRNA(Arg) for crystallography; point mutations in active site |
How to Study the arginyl-tRNA--protein transferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro transferase assay | Enzymatic activity (arginine incorporation) | Kinetic studies, inhibitor testing |
| X-ray crystallography | Three-dimensional structure of enzyme-tRNA-substrate complex | Mechanistic insights, drug design |
| Mass spectrometry | Identification and quantification of arginylated proteins | Substrate discovery, site mapping |
| CRISPR knockout screening | Genes required for arginylation-dependent phenotypes | Functional genomics |
| Western blot with anti-arginine antibodies | Levels of arginylated proteins | Validation of specific substrates |
| Fluorescence microscopy | Subcellular localization of ATE1 and substrates | Dynamic regulation studies |
| Ribo-seq | Translation efficiency of ATE1 or substrates | Global effects on protein synthesis |
| RNA-seq | Transcriptional changes upon ATE1 modulation | Pathway analysis |
Biochemical Assays for Transferase Activity
In vitro assays using purified ATE1, arginyl-tRNA(Arg), and acceptor proteins can directly measure arginine transfer by detecting incorporated radioactivity or using mass spectrometry. These assays are essential for kinetic characterization and inhibitor screening.
Structural Biology (X-ray Crystallography and Cryo-EM)
Crystal structures of ATE1 in complex with tRNA and substrate analogs have revealed the catalytic mechanism and tRNA recognition. These methods guide mutagenesis and drug design.
Proteomics and Mass Spectrometry
Mass spectrometry-based proteomics can identify arginylated proteins and map modification sites, providing a global view of substrates. Enrichment of N-terminal peptides is often used.
Genetic and CRISPR Screens
CRISPR knockout or knockdown screens can identify genes that modulate arginylation or are required for its function. Reporter systems with N-degron fusions enable high-throughput screening.
How CRISPR Can Be Used to Study GO:0004057 arginyl-tRNA--protein transferase activity
Knockout
CRISPR knockout of ATE1 in cell lines or model organisms abolishes arginyl-tRNA--protein transferase activity, enabling studies of its loss-of-function phenotypes. Knockout mice show embryonic lethality, highlighting its essential role.
Point Mutation
Introducing point mutations in the catalytic residues of ATE1 (e.g., cysteine to alanine) via CRISPR can dissect the enzymatic mechanism without affecting protein stability. Similarly, mutating the N-terminal acceptor residue of a substrate can prevent its arginylation.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) into the endogenous ATE1 locus allows for affinity purification and localization studies. Knock-in of mutant tRNA(Arg) or substrate proteins can also be used to study specificity.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of ATE1 can elevate arginylation levels, useful for gain-of-function studies in cancer and metabolism. Overexpression models help identify downstream effects and potential therapeutic targets.
How EDITGENE Supports arginyl-tRNA--protein transferase activity Research
Researchers studying arginyl-tRNA--protein transferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as cancer progression or metabolic regulation. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes like ATE1 and its substrates.
Contact EDITGENE today to design your custom CRISPR model for arginyl-tRNA--protein transferase activity research.
Frequently Asked Questions About arginyl-tRNA--protein transferase activity
What is arginyl-tRNA--protein transferase activity?
It is the enzyme activity that transfers the amino acid arginine from arginyl-tRNA to the N-terminus of a protein, as defined by GO:0004057.
What genes are involved in arginyl-tRNA--protein transferase activity?
The main gene is ATE1 in eukaryotes, which encodes the enzyme. Other genes include substrate proteins like TUG and ACAD10, and tRNA(Arg).
What is the function of ATE1?
ATE1 catalyzes arginylation, a post-translational modification that regulates protein stability, localization, and interactions, often through the N-degron pathway.
How is arginyl-tRNA--protein transferase activity regulated?
It is regulated by stress signals, insulin signaling, and substrate availability, including oxidation of N-terminal cysteine residues.
What diseases are associated with arginyl-tRNA--protein transferase activity?
Dysregulation is linked to cancer, metabolic disorders, and potentially neurodegeneration and infectious diseases.
What is the N-degron pathway?
The N-degron pathway is a protein degradation system where the N-terminal residue of a protein acts as a degradation signal; arginylation can create such a signal.
Can arginyl-tRNA--protein transferase activity be inhibited?
Yes, small molecule inhibitors or genetic knockout can inhibit the activity, and structural studies are guiding inhibitor development.
What model systems are used to study arginyl-tRNA--protein transferase activity?
Yeast, mouse models, and human cell lines are commonly used, with CRISPR knockout and overexpression being key approaches.
What is the reaction catalyzed by arginyl-tRNA--protein transferase?
The reaction is: N-terminal L-alpha-aminoacyl-[protein] + L-arginyl-tRNA(Arg) = H+ + N-terminal L-arginyl-L-amino acid-[protein] + tRNA(Arg).
How can I study arginyl-tRNA--protein transferase activity in my lab?
You can use biochemical assays, CRISPR knockout/knock-in models, proteomics, and structural biology; EDITGENE offers custom services for these approaches.
Conclusion
Arginyl-tRNA--protein transferase activity (GO:0004057) is a fundamental enzymatic function that mediates arginylation, a conserved post-translational modification with broad implications for protein stability, metabolism, and disease. Structural and biochemical studies have elucidated the molecular mechanism, while genetic models have revealed its roles in cancer, metabolic regulation, and stress responses. Continued research using CRISPR-based tools will further uncover the therapeutic potential of targeting this activity.
References
- 1. Abeywansha T et al.. 2023. The structural basis of tRNA recognition by arginyl-tRNA-protein transferase.. Nat Commun 14(1):2232 PMID: 37076488
- 2. Kim BH et al.. 2022. Crystal structure of the Ate1 arginyl-tRNA-protein transferase and arginylation of N-degron substrates.. Proc Natl Acad Sci U S A 119(31):e2209597119 PMID: 35878037
- 3. Habtemichael EN et al.. 2021. Insulin-stimulated endoproteolytic TUG cleavage links energy expenditure with glucose uptake.. Nat Metab 3(3):378-393 PMID: 33686286
- 4. Sharma R et al.. 2018. Insights on a putative aminoacyl-tRNA-protein transferase of Leishmania major.. PLoS One 13(9):e0203369 PMID: 30208112
- 5. Balzi E et al.. 1990. Cloning and functional analysis of the arginyl-tRNA-protein transferase gene ATE1 of Saccharomyces cerevisiae.. J Biol Chem 265(13):7464-71 PMID: 2185248
- 6. Li J et al.. 1995. Inactivation of arginyl-tRNA protein transferase by a bifunctional arsenoxide: identification of residues proximal to the arsenoxide site.. Biochemistry 34(1):139-47 PMID: 7819189
- 7. Nawale L et al.. 2025. ATE1 promotes breast cancer progression via arginylation-dependent regulation of MAPK-MYC signaling.. Cell Commun Signal 23(1):390 PMID: 40898325
- 8. Shim SM et al.. 2023. The Cys-N-degron pathway modulates pexophagy through the N-terminal oxidation and arginylation of ACAD10.. Autophagy 19(6):1642-1661 PMID: 36184612
